Clinical Trials Logo

Leukemia, Biphenotypic, Acute clinical trials

View clinical trials related to Leukemia, Biphenotypic, Acute.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03195010 Terminated - Clinical trials for Acute Myeloid Leukemia

Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia

Start date: June 9, 2017
Phase: Phase 2
Study type: Interventional

This pilot clinical trial compares the safety of two different platelet transfusion "thresholds" among patients with blood cancer or treatment-induced thrombocytopenia whose condition requires anticoagulant medication (blood thinners) for blood clots. Giving relatively fewer platelet transfusions may reduce the side effects of frequent platelet transfusions without leading to undue bleeding.

NCT ID: NCT02419755 Terminated - Clinical trials for Acute Myeloid Leukemia

Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

Start date: April 14, 2015
Phase: Phase 2
Study type: Interventional

This study will test the safety and effectiveness of adding bortezomib and vorinostat to other chemotherapy drugs commonly used to treat relapsed or refractory leukemia. Both drugs have been approved by the Food and Drug Administration (FDA) to treat other cancers in adults, but they have not yet been approved tor treatment younger patients with leukemia. PRIMARY OBJECTIVE - To estimate the overall response rate of patients with MLL rearranged (MLLr) hematologic malignancies receiving bortezomib and vorinostat in combination with a chemotherapy backbone. SECONDARY OBJECTIVES - Estimate event-free and overall-survival. - Describe toxicities experienced by participants during treatment. OTHER PRESPECIFIED OBJECTIVES - To identify all genomic lesions by comprehensive whole genome, exome and transcriptome sequencing on all patients. - To compare minimal residual disease (MRD) results by three modalities: flow cytometry, polymerase chain reaction (PCR) and deep sequencing.

NCT ID: NCT02399917 Terminated - Clinical trials for Refractory Acute Myeloid Leukemia

Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Start date: April 20, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects lirilumab and azacitidine and to see how well they work in treating patients with acute myeloid leukemia that has not responded to treatment or has returned after a period of improvement. Monoclonal antibodies, such as lirilumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving lirilumab with azacitidine may be an effective treatment for relapsed or refractory acute myeloid leukemia.

NCT ID: NCT01761682 Terminated - Clinical trials for Lymphoblastic Lymphoma

Acute Lymphoblastic Leukemia Registry at Asan Medical Center

Start date: January 2013
Phase:
Study type: Observational [Patient Registry]

The investigators would like to propose a prospective longitudinal observational cohort study for patients who will be diagnosed and/or treated for acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, to use the acquired data for fundamentals of other retrospective analysis.

NCT ID: NCT01028716 Terminated - Clinical trials for Myelodysplastic Syndrome

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Start date: May 19, 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well donor peripheral blood stem cell (PBSC) transplant works in treating patients with hematologic malignancies. Cyclophosphamide when added to tacrolimus and mycophenolate mofetil is safe and effective in preventing severe graft-versus-host disease (GVHD) in most patients with hematologic malignancies undergoing transplantation of bone marrow from half-matched (haploidentical) donors. This approach has extended the transplant option to patients who do not have matched related or unrelated donors, especially for patients from ethnic minority groups. The graft contains cells of the donor's immune system which potentially can recognize and destroy the patient's cancer cells (graft-versus-tumor effect). Rejection of the donor's cells by the patient's own immune system is prevented by giving low doses of chemotherapy (fludarabine phosphate and cyclophosphamide) and total-body irradiation before transplant. Patients can experience low blood cell counts after transplant. Using stem cells and immune cells collected from the donor's circulating blood may result in quicker recovery of blood counts and may be more effective in treating the patient's disease than using bone marrow.